CY1122307T1 - Μεθοδοι και συνθεσεις για παραδοση της ιδουρονικης-2-σουλφατασης στο κνς - Google Patents

Μεθοδοι και συνθεσεις για παραδοση της ιδουρονικης-2-σουλφατασης στο κνς

Info

Publication number
CY1122307T1
CY1122307T1 CY20191101211T CY191101211T CY1122307T1 CY 1122307 T1 CY1122307 T1 CY 1122307T1 CY 20191101211 T CY20191101211 T CY 20191101211T CY 191101211 T CY191101211 T CY 191101211T CY 1122307 T1 CY1122307 T1 CY 1122307T1
Authority
CY
Cyprus
Prior art keywords
sulfatase
compositions
methods
iduronic
cns
Prior art date
Application number
CY20191101211T
Other languages
English (en)
Inventor
Gaozhong Zhu
Kris Lowe
Zahra Shahrokh
James Christian
Rick Fahrner
Jing Pan
Teresa Leah Wright
Pericles Calias
Original Assignee
Shire Human Genetic Therapies, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46888843&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1122307(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Human Genetic Therapies, Inc. filed Critical Shire Human Genetic Therapies, Inc.
Publication of CY1122307T1 publication Critical patent/CY1122307T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Abstract

Η παρούσα εφεύρεση παρέχει, μεταξύ άλλων, συνθέσεις και μεθόδους για παράδοση στο ΚΝΣ λυσοσωματικών ενζύμων για αποτελεσματική θεραπεία νόσων λυσοσωματικής αποθήκευσης. Σε μερικές υλοποιήσεις, η παρούσα εφεύρεση περιλαμβάνει ένα σταθερό σκεύασμα για απευθείας ενδορραχιαία χορήγηση στο ΚΝΣ που περιλαμβάνει μία πρωτεΐνη ιδουρονική-2-σουλφατάση (I2S), άλας και ένα πολυσορβικό επιφανειοδραστικό για την θεραπεία του συνδρόμου Hunter.
CY20191101211T 2010-06-25 2019-11-19 Μεθοδοι και συνθεσεις για παραδοση της ιδουρονικης-2-σουλφατασης στο κνς CY1122307T1 (el)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US35885710P 2010-06-25 2010-06-25
US36078610P 2010-07-01 2010-07-01
US38786210P 2010-09-29 2010-09-29
US201161435710P 2011-01-24 2011-01-24
US201161442115P 2011-02-11 2011-02-11
US201161476210P 2011-04-15 2011-04-15
US201161495268P 2011-06-09 2011-06-09
PCT/US2011/041925 WO2011163649A2 (en) 2010-06-25 2011-06-25 Methods and compositions for cns delivery of iduronate-2-sulfatase

Publications (1)

Publication Number Publication Date
CY1122307T1 true CY1122307T1 (el) 2021-01-27

Family

ID=46888843

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20191101211T CY1122307T1 (el) 2010-06-25 2019-11-19 Μεθοδοι και συνθεσεις για παραδοση της ιδουρονικης-2-σουλφατασης στο κνς
CY20211100914T CY1124703T1 (el) 2010-06-25 2021-10-20 Μεθοδοι και συνθεσεις για παραδοση της ιδουρονικης-2-σουλφατασης στο κνς

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20211100914T CY1124703T1 (el) 2010-06-25 2021-10-20 Μεθοδοι και συνθεσεις για παραδοση της ιδουρονικης-2-σουλφατασης στο κνς

Country Status (24)

Country Link
US (1) US8545837B2 (el)
EP (3) EP3964229A1 (el)
JP (1) JP6045492B2 (el)
KR (5) KR102603430B1 (el)
CN (1) CN103179980B (el)
AU (4) AU2011270669B2 (el)
CA (1) CA2805448A1 (el)
CY (2) CY1122307T1 (el)
DK (1) DK2593131T3 (el)
ES (1) ES2754234T3 (el)
HR (1) HRP20191924T1 (el)
IL (3) IL284599B2 (el)
LT (1) LT2593131T (el)
ME (1) ME03649B (el)
MX (2) MX2020001395A (el)
NZ (2) NZ702808A (el)
PL (2) PL2593131T3 (el)
RS (1) RS59469B1 (el)
RU (1) RU2660348C2 (el)
SI (1) SI2593131T1 (el)
TW (1) TWI611808B (el)
UA (1) UA115649C2 (el)
WO (1) WO2011163649A2 (el)
ZA (1) ZA201300672B (el)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2472937C (en) 2002-01-11 2014-06-17 Biomarin Pharmaceutical, Inc. Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
JP5901877B2 (ja) 2007-07-27 2016-04-13 アーメイゲン・テクノロジーズ・インコーポレイテッドＡｒｍａｇｅｎ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃ． 中枢神経系のα−Ｌ−イデュロニダーゼ活性を増加させるための方法および組成物
EP2588130B1 (en) 2010-06-25 2016-08-17 Shire Human Genetic Therapies, Inc. Cns delivery of therapeutic agents
RU2012154576A (ru) 2010-06-25 2014-07-27 Шир Хьюман Дженетик Терапис, Инк. Способы и композиции для доставки к цнс гепаран-n-сульфатазы
IL291556B2 (en) 2010-06-25 2024-02-01 Shire Human Genetic Therapies Methods and compositions for administration of arylsulfatase A to the central nervous system
RU2660348C2 (ru) 2010-06-25 2018-07-05 Шир Хьюман Дженетик Терапис, Инк. Способы и композиции для доставки в цнс идуронат-2-сульфатазы
NZ702800A (en) 2010-06-25 2017-03-31 Shire Human Genetic Therapies Methods and compositions for cns delivery of heparan n-sulfatase
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
JP6208658B2 (ja) 2011-07-05 2017-10-04 バイオアシス テクノロジーズ インコーポレイテッド ｐ９７−抗体結合体および使用方法
US20140377244A1 (en) 2011-12-23 2014-12-25 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
AU2012358223B2 (en) * 2011-12-23 2018-01-18 Takeda Pharmaceutical Company Limited Treatment of cognitive impairment of Hunter syndrome by intrathecal delivery of iduronate-2-sulfatase
WO2013148277A1 (en) 2012-03-30 2013-10-03 Shire Human Genetic Therapies, Inc. Subcutaneous administration of iduronate- 2-sulfatase
US20140004097A1 (en) 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
EP2880156B1 (en) 2012-07-31 2017-08-23 biOasis Technologies Inc Dephosphorylated lysosomal storage disease proteins and methods of use thereof
EA039246B1 (ru) * 2012-12-06 2021-12-22 Шир Хьюман Дженетик Терапис, Инк. Способ лечения когнитивных нарушений, связанных с синдромом хантера
CN105263958B (zh) 2013-03-13 2019-09-27 比奥阿赛斯技术有限公司 p97片段及其应用
CN115120746A (zh) * 2013-05-15 2022-09-30 明尼苏达大学董事会 腺相关病毒介导的基因向中枢神经系统转移
JP6603227B2 (ja) 2014-02-03 2019-11-06 バイオアシス テクノロジーズ インコーポレイテッド Ｐ９７融合タンパク質
DK3107562T3 (da) 2014-02-19 2019-12-16 Bioasis Technologies Inc P97-ids-fusionsproteiner
US10058619B2 (en) 2014-05-01 2018-08-28 Bioasis Technologies, Inc. P97-polynucleotide conjugates
MA40954A (fr) * 2014-11-14 2017-09-19 Shire Human Genetic Therapies Détermination de niveaux de glycosaminoglycane par spectrométrie de masse
US10967073B2 (en) 2015-05-07 2021-04-06 The Mclean Hospital Corporation Glucocerebrosidase gene therapy for Parkinson's disease
KR20220082100A (ko) * 2015-05-15 2022-06-16 리젠츠 오브 더 유니버시티 오브 미네소타 중추 신경계로의 아데노-연관 치료적 전달
KR20170004814A (ko) * 2015-07-02 2017-01-11 주식회사 녹십자 헌터증후군 치료제
WO2017003270A1 (ko) * 2015-07-02 2017-01-05 주식회사 녹십자 헌터증후군 치료제 및 치료방법
SG11201805598WA (en) * 2015-12-30 2018-07-30 Green Cross Corp Methods and compositions for treating hunter syndrome
EP3402533B1 (en) * 2016-01-15 2021-08-04 Sangamo Therapeutics, Inc. Methods and compositions for the treatment of neurologic disease
JP2019509270A (ja) * 2016-02-17 2019-04-04 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド アリールスルファターゼａのｃｎｓ送達のための方法および組成物
AU2017222620B2 (en) * 2016-02-24 2022-06-16 Biomarin Pharmaceutical Inc. Targeted therapeutic lysosomal enzyme fusion proteins, associated formulations and uses thereof
JP7171439B2 (ja) 2016-04-15 2022-11-15 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア ムコ多糖症ｉｉ型を処置するための遺伝子療法
CN110114078B (zh) * 2016-12-28 2024-01-30 Jcr制药股份有限公司 冷冻干燥制剂
KR20190139951A (ko) 2017-04-14 2019-12-18 리젠엑스바이오 인크. 인간 뉴런 또는 신경교 세포에 의해 생성된 재조합 인간 이두로네이트-2 설파타제(ids)를 이용한 뮤코다당증 ii형의 치료
US11819539B2 (en) 2017-09-22 2023-11-21 The Trustees Of The University Of Pennsylvania Gene therapy for treating Mucopolysaccharidosis type II
MA50746A (fr) 2017-10-02 2020-08-12 Denali Therapeutics Inc Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive
JP7060235B2 (ja) * 2018-05-18 2022-04-26 国立大学法人広島大学 変異型イズロン酸－２－スルファターゼの機能回復薬剤のスクリーニング方法
KR20190136271A (ko) * 2018-05-30 2019-12-10 주식회사 녹십자 대뇌 측뇌실 투여에 의해 헌터증후군을 치료하기 위한 방법 및 조성물
US11738068B2 (en) 2018-06-25 2023-08-29 Jcr Pharmaceuticals Co., Ltd. Protein-containing aqueous liquid formulation
KR20200047937A (ko) * 2018-10-26 2020-05-08 재단법인 목암생명과학연구소 Ids를 포함하는 융합 단백질 및 이의 용도
US20220002688A1 (en) 2018-12-20 2022-01-06 Armagen, Inc. Purification of iduronate-2-sulfatase immunoglobulin fusion protein

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
US6063378A (en) * 1997-08-22 2000-05-16 Seikagaku Corporation Therapeutic agent for herniated intervertebral disc
KR20010101131A (ko) 1998-12-07 2001-11-14 추후기재 폼페병의 치료 방법
US6217552B1 (en) 1999-03-01 2001-04-17 Coaxia, Inc. Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma
US20020052311A1 (en) 1999-09-03 2002-05-02 Beka Solomon Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
US6534300B1 (en) 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
US20020099025A1 (en) 1999-12-30 2002-07-25 Heywood James A. Treatment of neurological disorders
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20040005309A1 (en) 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
JP4641705B2 (ja) 2001-04-30 2011-03-02 ザイストール セラピューティクス， インコーポレイテッド 治療的タンパク質の亜細胞標的化
WO2003102583A1 (en) 2002-05-29 2003-12-11 Symbiontics, Inc. Targeted therapeutic proteins
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
AU2002347910A1 (en) 2001-10-16 2003-04-28 Symbiontics Inc. Methods and compositions for targeting proteins across the blood brain barrier
EP1503788B1 (en) 2002-04-25 2011-06-29 Shire Human Genetic Therapies, Inc. Treatment of alpha-galactosidase a deficiency
EP1587923B1 (en) 2003-01-22 2011-08-24 Duke University Improved constructs for expressing lysosomal polypeptides
ES2686775T3 (es) * 2003-01-31 2018-10-19 Mount Sinai School Of Medicine Of New York University Terapia de combinación para tratar trastornos de deficiencia de proteínas
US7442372B2 (en) * 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
WO2005074888A2 (en) 2004-02-03 2005-08-18 Biodelivery Sciences International, Inc. Replacement enzyme cochleates
JP2007523648A (ja) 2004-02-06 2007-08-23 バイオマリン ファーマシューティカル インコーポレイテッド 高リン酸化リソソーム酵素製剤及びそれらの使用
DE602005020745D1 (de) 2004-02-10 2010-06-02 Zystor Therapeutics Inc Saure alpha-glukosidase und fragmente davon
US20050208090A1 (en) 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
JPWO2006121199A1 (ja) 2005-05-11 2008-12-18 日本ケミカルリサーチ株式会社 脂質小胞体組成物
AR059089A1 (es) 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
GB0611463D0 (en) 2006-06-09 2006-07-19 Novartis Ag Organic compounds
CA2680189A1 (en) 2007-03-06 2008-09-12 Saint Louis University Modified enzyme and treatment method
NZ709704A (en) * 2007-11-30 2017-03-31 Abbvie Biotechnology Ltd Protein formulations and methods of making same
US7722865B2 (en) 2008-01-18 2010-05-25 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
PL2279210T3 (pl) 2008-05-07 2017-10-31 Biomarin Pharm Inc Lizosomalne peptydy kierujące i ich zastosowania
RU2012154576A (ru) 2010-06-25 2014-07-27 Шир Хьюман Дженетик Терапис, Инк. Способы и композиции для доставки к цнс гепаран-n-сульфатазы
RU2660348C2 (ru) 2010-06-25 2018-07-05 Шир Хьюман Дженетик Терапис, Инк. Способы и композиции для доставки в цнс идуронат-2-сульфатазы
EP2588130B1 (en) 2010-06-25 2016-08-17 Shire Human Genetic Therapies, Inc. Cns delivery of therapeutic agents
EP2588132A4 (en) 2010-06-25 2014-10-15 Shire Human Genetic Therapies METHOD AND COMPOSITIONS FOR DELIVERING BETA GALACTOCEREBROSIDASE INTO THE CNS
IL291556B2 (en) 2010-06-25 2024-02-01 Shire Human Genetic Therapies Methods and compositions for administration of arylsulfatase A to the central nervous system
JP2012062312A (ja) * 2010-08-19 2012-03-29 Yoshikatsu Eto ハンター症候群の治療剤

Also Published As

Publication number Publication date
US20110318323A1 (en) 2011-12-29
KR102151889B1 (ko) 2020-09-04
CN103179980B (zh) 2016-09-28
UA115649C2 (uk) 2017-12-11
AU2019203515A1 (en) 2019-06-06
TWI611808B (zh) 2018-01-21
NZ702808A (en) 2016-08-26
ES2754234T3 (es) 2020-04-16
KR20130043165A (ko) 2013-04-29
RU2660348C2 (ru) 2018-07-05
TW201206463A (en) 2012-02-16
LT2593131T (lt) 2019-10-25
AU2021202579B2 (en) 2023-06-29
AU2019203515B2 (en) 2021-01-28
CY1124703T1 (el) 2022-07-22
WO2011163649A3 (en) 2012-05-10
IL284599A (en) 2021-08-31
DK2593131T3 (da) 2019-10-14
AU2011270669B2 (en) 2017-01-05
IL284599B2 (en) 2024-02-01
PL2593131T3 (pl) 2020-01-31
AU2021202579A1 (en) 2021-05-27
RS59469B1 (sr) 2019-11-29
AU2017202219A1 (en) 2017-04-27
KR102356192B1 (ko) 2022-02-08
RU2012154575A (ru) 2014-07-27
CA2805448A1 (en) 2011-12-29
HRP20191924T1 (hr) 2020-01-10
IL268085B (en) 2021-07-29
KR20220015506A (ko) 2022-02-08
KR102603430B1 (ko) 2023-11-16
AU2011270669A1 (en) 2013-02-14
EP2593131A2 (en) 2013-05-22
IL223716B (en) 2019-08-29
NZ605863A (en) 2015-02-27
EP3626258B1 (en) 2021-08-04
EP2593131B1 (en) 2019-08-21
KR20230159646A (ko) 2023-11-21
SI2593131T1 (sl) 2019-11-29
EP2593131A4 (en) 2014-01-22
ZA201300672B (en) 2017-11-29
US8545837B2 (en) 2013-10-01
JP6045492B2 (ja) 2016-12-14
EP3626258A1 (en) 2020-03-25
KR20190008996A (ko) 2019-01-25
KR20200104433A (ko) 2020-09-03
ME03649B (me) 2020-07-20
IL284599B1 (en) 2023-10-01
AU2017202219B2 (en) 2019-02-21
WO2011163649A2 (en) 2011-12-29
IL268085A (en) 2019-08-29
CN103179980A (zh) 2013-06-26
JP2013530989A (ja) 2013-08-01
MX2020001395A (es) 2022-03-24
EP3964229A1 (en) 2022-03-09
PL3626258T3 (pl) 2022-01-17
MX2013000322A (es) 2013-04-03

Similar Documents

Publication Publication Date Title
CY1122307T1 (el) Μεθοδοι και συνθεσεις για παραδοση της ιδουρονικης-2-σουλφατασης στο κνς
CY1124910T1 (el) Μεθοδοι και συνθεσεις για παραδοση στο κνς της αρυλοσουλφατασης α
BR112012033214A2 (pt) método e composições para distribuição no snc de iduronato-2-sulfatase
WO2011163647A3 (en) Methods and compositions for cns delivery of heparan n-sulfatase
WO2011163651A3 (en) METHODS AND COMPOSITIONS FOR CNS DELIVERY OF β-GALACTOCEREBROSIDASE
EA201491285A1 (ru) Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты
EA201492021A1 (ru) Антительный состав
PH12014502778B1 (en) Antibody formulation
SG195141A1 (en) Combination of panobinostat and ruxolitinib in the treatment of cancer suchas a myeloproliferative neoplasm
EA200870264A1 (ru) Композиция антител
BR112014010814A2 (pt) composições de herbicida/fitoprotetor contendo amidas do ácido n-(tetrazol-5-il) aril carboxílico e amidas do ácido n-(triazol-5-il) aril carboxílico
EA201491578A1 (ru) Подкожное введение идуронат-2-сульфатазы
WO2013096899A3 (en) Stable formulations for cns delivery of arylsulfatase a
AR122036A2 (es) Composiciones farmacéuticas estables para la administración intratecal de arisulfatasa a
TR200900880A2 (tr) Tek bir dozaj formunda kombine edilen farmasötik bileşimler.
EA201001568A1 (ru) Инкапсуляция биологически активных агентов
EA201201529A1 (ru) Комбинация ингибиторов ксантиноксидазы и статинов и ее применение
EA202192397A3 (ru) Интраназальные биоадгезивные тестостероновые составы в виде гелей и их применение для лечения мужского гипогонадизма
TR200806299A2 (tr) Çözünürlük artırıcı farmasötik formülasyon
TN2013000494A1 (en) Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm
TR201203087A2 (tr) Seftibüten ve klavulanik asit formülasyonları.
TR201203085A2 (tr) Sefetamet ve klavulanik asit içeren bileşimler.